Sumselterkini.co.id, HANOI, Vietnam, 05 Desember 2023 (GLOBE NEWSWIRE) — Perusahaan pengujian genetik terkemuka di Vietnam, Gene Solutions, yang mengkhususkan diri dalam mendeteksi keberadaan penyakit tertentu berdasarkan penanda genetiknya, memberikan dampak luar biasa pada Kongres ESMO Asia 2023, salah satu dari konferensi onkologi paling bergengsi yang diadakan di Singapura dari tanggal 1 hingga 3 Desember.
ESMO Asia adalah tempat para ahli internasional terkemuka, pemimpin opini utama, dan asosiasi onkologi bertemu setiap tahun untuk mempresentasikan dan mendiskusikan kemajuan ilmiah dan klinis terkini dalam bidang onkologi di kawasan Asia-Pasifik dan dunia.
Sebagai satu-satunya perwakilan Asia Tenggara pada kongres tahun 2023, Gene Solutions memperkenalkan pencapaiannya dalam Next-Generation Sequencing (NGS), yang menyajikan langkah maju yang signifikan dalam pengobatan yang dipersonalisasi dalam pengobatan kanker. Tim penelitian dan pengembangan menyajikan lima laporan, termasuk presentasi lisan dan empat poster yang menggambarkan keuntungan klinis dari pengujian genetik untuk skrining dan pelacakan kanker. Dua presentasi dianugerahi Travel Merit Award.
Gene Solutions telah mencapai kemajuan yang mengesankan di kawasan ini, hadir di Vietnam, Thailand, Filipina, Malaysia, Indonesia, dan sekarang Singapura. Laboratorium keenam yang baru dibuka di Singapura merupakan indikasi jelas atas pengakuan dan kerja sama dari pembangkit tenaga listrik global ini. Hal ini juga menjadi tuan rumah pertemuan dengan tema “Solusi Satu Atap untuk Semua Pasien Kanker”, yang mempertemukan para ahli dari enam negara Asia Tenggara.
Earlier in 2023, Gene Solutions’ clinical research success was recognized at The ASCO Breakthrough in Japan, with two ASCO Breakthrough Abstract Awards. They were selected for a prominent press conference to highlight the exceptional outcomes of their clinical validation study, K-DETEK.
This pioneering company is on a mission to combat these ailments and improve patient care in Southeast Asia. It has developed Screening for the Presence of Tumor by Methylation And Size (SPOT-MAS) – a multimodal liquid biopsy-based assay that can detect the five most common cancer types (liver, breast, colorectal, gastric, lung cancer).
In April 2022, the first analytical validation of SPOT-MAS test was conducted on a cohort of 738 patients, 1550 healthy individuals and published in the esteemed journal, eLife (eLife.89083.2). This proved SPOT-MAS’ ability to detect cancer patients with a sensitivity of 72.4% and a specificity of 97.0%. With products like SPOT-MAS, OncoGS, K-TRACK, K-4CARE, Gene Solutions has been at the forefront of applying liquid biopsy technology to support screening, diagnosis, guiding and monitoring treatment for various types of cancer.
Gene Solutions was co-founded in 2017 by Dr. Nguyen Hoai Nghia (CEO), Dr. Nguyen Huu Nguyen (Deputy CEO), and Dr. Giang Hoa (R&D Head). They have strong backgrounds in genetics, cancer biology, clinical medicine, biotechnology.
After studying cancer biology and genetics in the US, Dr. Nghia wished to establish cutting-edge technologies in Vietnam. That was when “Gene Solutions” as an idea came to be. They aim to create a solution that will be more accessible, affordable, and widely accessible, thereby benefiting millions of people in Southeast Asia.
“It was an exciting experience to present our research at this esteemed event for the first time, and an honor to be rewarded for our efforts. We are proud of our six-year journey in Vietnam developing NGS. Gene Solutions is leading a much-needed paradigm shift in healthcare by embracing the most recent developments in genetic research, encouraging preventive care, and motivating people to take control of their health,” said Dr. Nguyen Huu Nguyen.[***]
